FDA warns Malaysian seafood processor Sen Up Huat over inadequate histamine controls in its seafood safety plan for bonito and other fish.
What happened
FDA inspected the facility on October 23 & 24, 2023 and issued an FDA-483, a list of inspectional observations. It found the firm’s Hazard Analysis and Critical Control Point (HACCP) plan for histamine-forming seafood, including frozen raw bonito, lacked adequate critical limits at receiving to control histamine formation after capture aboard the harvest vessel. The company responded on November 10, 2023, but FDA found the response inadequate.
What FDA found
The company’s seafood safety plan for frozen raw bonito and other histamine-forming fish did not set adequate required limits at receiving to control histamine formation after capture on the harvest vessel.
21 CFR 123.6(c)(3)
What FDA wants
FDA asks the company to respond in writing within 15 working days with specific corrections and supporting documentation, such as HACCP and verification records, or explain any delay and when remaining corrections will be made.
Who should pay attention
- seafood importers and brands sourcing from Malaysian processors
- companies that buy frozen raw bonito or other histamine-forming fish
- suppliers relying on harvest vessel records for histamine control
This is a summary. Read the original letter on fda.gov.